Developing cGMP analog drug products

Mireca Medicines GmbH, Tübingen, is an expanding, preclinical stage company pioneering the development of proprietary cyclic guanosine monophosphate (cGMP)-analogs and drug delivery technologies to treat diseases caused by a dysregulation of cGMP, affecting protein kinase G (PKG). Mireca’s lead program focusses on the inhibition of PKG for neuroprotection and has obtained positive preclinical data for inherited retinal diseases (IRD). IRD-type disease include Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis, and Stargardt’s disease.